AffyImmune Therapeutics Expands Board of Directors with Key Appointments

Share This Post

Key Highlights

  • AffyImmune Therapeutics announces the appointment of Rick Rutter, Ph.D., and Jorge Nieva, M.D., to its Board of Directors.
  • Appointments bolster AffyImmune’s AIC100 CAR T cell therapy development for advanced thyroid cancers and non-small cell lung cancer (NSCLC).
  • Rutter and Nieva bring decades of experience in CMC regulatory strategy and clinical oncology.
  • AffyImmune’s AIC100 is nearing completion of Phase 1 trials for thyroid cancer and moving toward Phase 2 for NSCLC.

Source: Business Wire

Notable Quotes

  • “I am delighted to join AffyImmune’s Board and to work with the management team to bring industry-best CMC and supply chain practices, and ready AIC100 for registrational trials and commercial launch.” Rick Rutter, Ph.D., Former Executive Vice President, Biotherapeutics Pharmaceutical Sciences at Pfizer; Expert Consultant
  • “Joining AffyImmune’s Board of Directors is an exciting opportunity to contribute to the expansion of AIC100 beyond advanced thyroid cancers, into larger indications such as NSCLC.”  Jorge Nieva, M.D., Associate Professor of Clinical Medicine at  Keck School of Medicine, University of Southern California

SoHC's Take

AffyImmune’s strategic appointments of Rick Rutter, Ph.D., and Jorge Nieva, M.D., signal a pivotal moment for the company as it progresses its innovative CAR T cell therapy, AIC100, toward advanced clinical trials. These new board members not only enhance the company’s expertise in regulatory strategy and oncology but also strengthen its ability to address significant unmet medical needs in thyroid cancer and NSCLC. This expansion marks a crucial step for AffyImmune as it readies AIC100 for commercialization, advancing toward transforming solid tumor treatment landscapes.

Heading

Key Highlights Novo Nordisk partners with Hims & Hers, LifeMD, and Rofor streamlined Wegovy® access through telehealth.Wegovy® now available at ...
/
Key Highlights Ro now offers all Wegovy® doses for $499/month via NovoCare® PharmacyDirect access to FDA-approved GLP-1 medication through the ...
/
Episode Details: Join us on the latest episode, hosted by Jared S. Taylor! Our Guest: Dr. Jim Bonnette, Chief Medical ...
/
Key Highlights 28% reductionin documentation time for care teams20% increasein patient engagement through automated outreachAI Agentsmanage SMS/voice outreach, scheduling, and ...
/
Key Highlights Warner Roberts appointed as Calibrate’s Chief Commercial OfficerWill lead commercial strategy to scale workplace obesity solutionsCalibrate members report ...
/
Key Highlights Fully integratedwith Castlight’s healthcare benefits app 24/7 on-demand carevia chat, video, and voice High-quality carefor common conditions delivered ...
/

More To Explore

Total
0
Share